In a randomised controlled trial comprising 48 patients with relapsing-remitting multiple sclerosis, supplementation with CoQ10 (500 mg/day for 3 months) resulted in a significant reduction in blood levels of the inflammatory biomarkers interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha). This evidence concerns the gene IL6 and relapsing-remitting multiple sclerosis.